Supplementary Figure and Table Legends from A Diverse Array of Cancer-Associated mtor Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529639

2023-01-01

Abstract:PDF file 82K, Supplementary Figure and Table Legends

What problem does this paper attempt to address?

Supplementary Figure 1 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529657.v1

2023-01-01

Abstract:PDF file 85K, mTOR pathway mutations
Supplementary Figure 3 from A Diverse Array of Cancer-Associated mtor Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529651.v1

2023-01-01

Abstract:PDF file 94K,Non-recurrent MTOR mutations confer different degrees of mTORC1 activation
Supplementary Figure 6 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529642.v1

2023-01-01

Abstract:PDF file 154K, Recurrent mTOR mutations mapped onto the crystal structure of mTOR
Supplementary Table 5 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529624

2023-01-01

Abstract:XLSX file 17K, All site-directed mutagenesis primers to generate mutant mTOR and Rheb1 are listed
Supplementary Figure Legends from Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells

Rajat Bhattacharya,Xiang-Cang Ye,Rui Wang,Xia Ling,Madonna McManus,Fan,Delphine Boulbes,Lee M. Ellis

DOI: https://doi.org/10.1158/0008-5472.22407995.v1

2023-01-01

Abstract:Legends for Supplementary Figures S1-S12.
Supplementary Figure 4 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529648

2023-01-01

Abstract:PDF file 143K, mTOR mutants alter Deptor binding and nutrient deprivation, but not sensitivity to mTOR inhibitors
Supplementary Figure 2 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529654

2023-01-01

Abstract:PDF file 106K, S2215Y mTOR activates mTORC1 signaling similar to WT and mutant PI3K-p110alpha
Supplementary Table 4 from A Diverse Array of Cancer-Associated mtor Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529627.v1

2023-01-01

Abstract:XLSX file 12K, All activating MTOR mutations from this study are listed
Supplementary Figure 5 from A Diverse Array of Cancer-Associated mtor Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529645.v1

2023-01-01

Abstract:PDF file 73K, mTOR R1208C, V2006L, R2152C, and R2430M fail to confer increased S6K1 phosphorylation
Supplementary Table 2 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529633

2023-01-01

Abstract:XLSX file 31K, All MTOR mutations from a literature search and the cBIO, COSMIC, and ICGC databases are listed
Supplementary Table 2 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529633.v1

2023-01-01

Abstract:XLSX file 31K, All MTOR mutations from a literature search and the cBIO, COSMIC, and ICGC databases are listed
Supplementary Table 1 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529636

2023-01-01

Abstract:XLSX file 89K, All mutations from the cBIO and COSMIC databases in mTOR pathway genes, excluding MTOR, are listed
Supplementary Table 3 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529630.v1

2023-01-01

Abstract:XLSX file 10K, Homologous mutations from S. pombe tor2 in H. sapiens MTOR are listed
Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Junying Zeng,Sharad Sharma,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22503690

2023-01-01

Abstract:PDF - 71K, Legends for Supplementary Figures 1 through 5.
Figure Legends for Supplementary Figures from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xiaowen Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chi,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461800.v1

2023-01-01

Abstract:Figure legends for Supplementary Figure S1 and Figure S2
Supplementary Figure Legends from Mir-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma

Jun Wei,Fei Wang,Ling-Yuan Kong,Shuo Xu,Tiffany Doucette,Sherise D. Ferguson,Yuhui Yang,Kayla McEnery,Krishan Jethwa,Olsi Gjyshi,Wei Qiao,Nicholas B. Levine,Frederick F. Lang,Ganesh Rao,Gregory N. Fuller,George A. Calin,Amy B. Heimberger

DOI: https://doi.org/10.1158/0008-5472.22394862.v1

2023-01-01

Abstract:Supplementary Figure Legends - PDF file 70K, Supplementary Figure Legends
A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity.

Brian C Grabiner,Valentina Nardi,Kıvanc Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H Beck,David M Sabatini

DOI: https://doi.org/10.1158/2159-8290.cd-13-0929

IF: 28.2

2014-01-01

Cancer Discovery

Abstract:Genes encoding components of the PI3K-AKT-mTOR signaling axis are frequently mutated in cancer, but few mutations have been characterized in MTOR, the gene encoding the mTOR kinase. Using publicly available tumor genome sequencing data, we generated a comprehensive catalog of mTOR pathway mutations in cancer, identifying 33 MTOR mutations that confer pathway hyperactivation. The mutations cluster in six distinct regions in the C-terminal half of mTOR and occur in multiple cancer types, with one cluster particularly prominent in kidney cancer. The activating mutations do not affect mTOR complex assembly, but a subset reduces binding to the mTOR inhibitor DEPTOR. mTOR complex 1 (mTORC1) signaling in cells expressing various activating mutations remains sensitive to pharmacologic mTOR inhibition, but is partially resistant to nutrient deprivation. Finally, cancer cell lines with hyperactivating MTOR mutations display heightened sensitivity to rapamycin both in culture and in vivo xenografts, suggesting that such mutations confer mTOR pathway dependency.
Supplementary Materials and Figure Legends 1-4 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Hongbin Ji,Zhenxiong Wang,Samanthi A. Perera,Danan Li,Mei-Chih Liang,Sara Zaghlul,Kate McNamara,Liang Chen,Mitchell Albert,Yanping Sun,Ruqayyah Al-Hashem,Lucian R. Chirieac,Robert Padera,Roderick T. Bronson,Roman K. Thomas,Levi A. Garraway,Pasi A. Jänne,Bruce E. Johnson,Lynda Chin,Kwok-Kin Wong

DOI: https://doi.org/10.1158/0008-5472.22367982.v1

2023-01-01

Abstract:Supplementary Materials and Figure Legends 1-4 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models
Supplementary Figure Legend from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER+ Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Yan Lu,Ming You,Zara Ghazoui,Pengyuan Liu,Peter T. Vedell,Weidong Wen,Ann M. Bode,Clinton J. Grubbs,Ronald A. Lubet

DOI: https://doi.org/10.1158/1940-6207.22524288

2023-01-01

Abstract:PDF file - 36K
Supplemental Figures and Tables Legends from Notch1 Mutations Are Drivers of Oral Tumorigenesis

Evgeny Izumchenko,Kening Sun,Siân Jones,Mariana Brait,Nishant Agrawal,Wayne M. Koch,Christine L. McCord,David R. Riley,Samuel V. Angiuoli,Victor E. Velculescu,Wei‐Wen Jiang,David Sidransky

DOI: https://doi.org/10.1158/1940-6207.22526591

2023-01-01

Abstract:Supplemental Figures and Tables legends

Supplementary Figure and Table Legends from A Diverse Array of Cancer-Associated <i>mtor</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 1 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 3 from A Diverse Array of Cancer-Associated <i>mtor</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 6 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 5 from A Diverse Array of Cancer-Associated <i>MTOR</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure Legends from Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells

Supplementary Figure 4 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 2 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 4 from A Diverse Array of Cancer-Associated <i>mtor</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 5 from A Diverse Array of Cancer-Associated <i>mtor</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 2 from A Diverse Array of Cancer-Associated <i>MTOR</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 2 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 1 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 3 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Figure Legends for Supplementary Figures from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure Legends from Mir-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma

A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity.

Supplementary Materials and Figure Legends 1-4 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Supplementary Figure Legend from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER<sup>+</sup> Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplemental Figures and Tables Legends from Notch1 Mutations Are Drivers of Oral Tumorigenesis

Supplementary Figure and Table Legends from A Diverse Array of Cancer-Associated &lt;i&gt;mtor&lt;/i&gt; Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity